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Dear Editor, 
We read with interest the findings from Matrajt et al.[1], who propose a novel approach to 
live attenuated influenza vaccine (LAIV) strain selection based on results from mathematical 
models. They suggest vaccine strains should be antigenically distant enough from pre-
existing immunity to allow vaccine replication, while remaining antigenically close enough 
to circulating strains to protect from infection. We fully agree this approach is worth 
exploring, not only for strain selection, but also for decisions about the optimal age and 
frequency of childhood immunization with LAIV. However, there are a number of 
complexities to LAIV immunogenicity worth highlighting that cannot be ignored if such 
strategies were to be used in practice.  
 
The proposed model assumes that pre-existing serum antibodies from prior infection or 
vaccination are the main driver of /$,9 µWDNH¶ DQG immunogenicity. Our own data using 
Russian-backbone LAIV in Gambian children aged 24-59 months partially support this, with 
pre-immunization serum haemagglutination inhibition (HAI) titre (but not T-cell response or 
mucosal IgA) being the key determinant of LAIV shedding[2]. We have recently stratified 
this cohort based on seropositivity to the H3N2 strain included in the vaccine (A/Hong 
Kong/4801/2014; A/HK), and two older H3N2 strains antigenically similar to those 
SRWHQWLDOO\ HQFRXQWHUHG GXULQJ WKH FKLOGUHQ¶V OLIHWLPH (A/Switzerland/9715293/2013; A/Sw 
or A/Texas/50/2012; A/Tex). Children who were A/HK+ (HAI titre t1:10) at baseline (n = 
169) were less likely to shed H3N2, compared to those seropositive to A/Sw or A/Tex (but 
A/HK seronegative, n = 28), or children seronegative (<1:10) to all three H3N2 strains (n = 
45, Figures 1A and 1B)). Shedding was not significantly different between seronegative 
children and those seropositive to A/Sw or A/Tex only. 
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However, the immunogenicity data reveal a more complex pattern.  While HAI 
seroconversion is significantly lower in A/HK+ children and reflects patterns of shedding, the 
T-cell and mucosal IgA responses follow different trends (Figure 1C). A t2-fold CD4+ T-
cell response is generated most often in children seronegative to all three strains, but at 
similar levels in A/HK+ or A/Sw+/A/Tex+ (A/HK-) children. In addition, prior serostatus has 
no impact on the likelihood of a t2-fold mucosal IgA response.  This is in keeping with our 
findings that shedding increases the odds of seroconversion and a T-cell response, but not 
mucosal IgA responses[2]. Furthermore, ~50% of children generated a T-cell response to 
A/HK Haemagglutinin despite being A/HK seropositive, challenging the view that giving 
LAIV may not be worthwhile in the face of pre-existing serum antibody immunity to vaccine 
strains. Similar T-cell data are observed for matrix and nucleoprotein (data not shown).  
Interpreting any such data is of course limited by the lack of a correlate of protection for 
LAIV, although both T-cells and IgA have been shown to protect in the absence of 
seroconversion and are likely to be co-correlates of protection, along with serum 
antibodies[3-7]. 
 
The approach taken by Matrajt et al.[1] to improve LAIV effectiveness is promising. Well-
designed immunogenicity studies in children to both inform and test further models could 
help refine our approach to LAIV use in the future.  
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Figure 1. Shedding and immunogenicity to Russian-backbone LAIV in Gambian 
children aged 24-59 months, stratified by pre-existing serum antibodies to H3N2 strains. 
A. Percentage of children shedding H3N2 at day 2 following LAIV. B. Cycle threshold (ct) 
from H3 haemagglutinin (HA)-specific reverse-transcriptase polymerase chain reaction 
assays on nasopharyngeal swabs as a marker of viral load at day 2 following LAIV. C. 
Immune responses to LAIV determined by responses at day 21 following immunization 
(definition of responses described previously[2]). T-cell response denotes H3 HA-specific 
CD4+ T-cells producing IFN-J and/or IL-2. A/HK = H3N2 A/Hong Kong/4801/2014, A/Sw 
= H3N2 A/Switzerland/9715293/2013, A/Tex = A/Texas/50/2012, Seronegative = 
haemagglutination inhibition titre <1:10 to A/HK, A/Sw and A/Tex, H3 HA = A/HK 
haemagglutinin, IgA = immunoglobulin A. **** p <0.0001, *** p<0.001, *p<0.05. ns = not 
VLJQLILFDQW DW S 3URSRUWLRQV FRPSDUHG ZLWK )LVKHU¶V H[DFW WHVW &W YDOXHV FRPSDUHG
using Kruskal-:DOOLVWHVWZLWK'XQQ¶VSRVW-test.   
  
 
  
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/c
id
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/c
id
/c
iz
7
7
3
/5
5
4
9
9
5
3
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
, T
h
u
s
h
a
n
 d
e
 S
ilv
a
 o
n
 2
3
 A
u
g
u
s
t 2
0
1
9
  
6
 
Fi
gu
re
 
1
 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz773/5549953 by University of Sheffield, Thushan de Silva on 23 August 2019
